Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Kronos Bio Q2 EPS $(0.59) Down From $(0.53) YoY

Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.59) per share. This is a 11.32 percent decrease over losses of $(0.53) per share from the same period last year.
byBill Haddad
August 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.59) per share. This is a 11.32 percent decrease over losses of $(0.53) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cogent Biosciences Announced Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib In Patients with Nonadvanced Systemic Mastocytosis 57% Median Best Improvement On MC-QoL And 78% Of Patients Reporting ≥1 Point Improvement On PGIS By Week 20

By Charles Gross
December 9, 4:16 PM
Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive initial data from the Company’s ongoing Phase

COGT

Read More

Earnings Preview: Enterprise Finl Servs

By Benzinga Insights
October 21, 2:11 PM
Enterprise Finl Servs (NASDAQ:EFSC) is set to give its latest quarterly earnings report on Monday, 2022-10-24. Here's what investors need to know before the announcement. Analysts estimate that Enterprise Finl Servs will report an earnings per share (EPS) of $1.24.

EFSC